These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 36949377)
1. Long Acting Ionically Paired Pamoate-based Suspension of Lurasidone: An exploration of Size Effects on in vitro Dissolution and in vivo Pharmacokinetic Behaviors. Li S; He Y; Sun D; Wang Z; Yu J; Ye J; He Z; Wang Y AAPS PharmSciTech; 2023 Mar; 24(4):83. PubMed ID: 36949377 [TBL] [Abstract][Full Text] [Related]
2. Intramuscularly injected long-acting testosterone-cholesterol prodrug suspension with three different particle sizes: extended in vitro release and enhanced in vivo safety. Li S; Wang Z; Yu J; Zhang C; Ye J; Liu H; Jiang Y; He Z; Wang Y Drug Deliv Transl Res; 2024 Apr; 14(4):1093-1105. PubMed ID: 37932630 [TBL] [Abstract][Full Text] [Related]
3. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: optimization, Patel MH; Mundada VP; Sawant KK Drug Dev Ind Pharm; 2019 Aug; 45(8):1242-1257. PubMed ID: 30880488 [No Abstract] [Full Text] [Related]
4. Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder. Pardhi VP; Flora S Biopharm Drug Dispos; 2020 Nov; 41(8-9):334-351. PubMed ID: 33080060 [TBL] [Abstract][Full Text] [Related]
5. Charge-assisted bond N Qian S; Wang S; Li Z; Wang X; Ma D; Liang S; Gao Y; Zhang J; Wei Y Int J Pharm; 2017 Feb; 518(1-2):335-341. PubMed ID: 28043915 [TBL] [Abstract][Full Text] [Related]
6. Design, Optimization, and Evaluation of Lurasidone Hydrochloride Nanocrystals. Shah S; Parmar B; Soniwala M; Chavda J AAPS PharmSciTech; 2016 Oct; 17(5):1150-8. PubMed ID: 26586537 [TBL] [Abstract][Full Text] [Related]
7. Effect of particle size on in vivo performances of long-acting injectable drug suspension. Ho MJ; Jeong MY; Jeong HT; Kim MS; Park HJ; Kim DY; Lee HC; Song WH; Kim CH; Lee CH; Choi YW; Choi YS; Han YT; Kang MJ J Control Release; 2022 Jan; 341():533-547. PubMed ID: 34902451 [TBL] [Abstract][Full Text] [Related]
8. Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride. Heng W; Su M; Cheng H; Shen P; Liang S; Zhang L; Wei Y; Gao Y; Zhang J; Qian S Mol Pharm; 2020 Jan; 17(1):84-97. PubMed ID: 31794225 [TBL] [Abstract][Full Text] [Related]
9. Specific surface area of mannitol rather than particle size dominant the dissolution rate of poorly water-soluble drug tablets: A study of binary mixture. Zhang K; Qian S; Liu Z; Liu H; Lin Z; Heng W; Gao Y; Zhang J; Wei Y Int J Pharm; 2024 Jul; 660():124280. PubMed ID: 38802025 [TBL] [Abstract][Full Text] [Related]
10. Enhanced oral bioavailability of lurasidone by self-nanoemulsifying drug delivery system in fasted state. Miao Y; Sun J; Chen G; Lili R; Ouyang P Drug Dev Ind Pharm; 2016 Aug; 42(8):1234-40. PubMed ID: 26582334 [TBL] [Abstract][Full Text] [Related]
11. Investigation of salt formation between memantine and pamoic acid: Its exploitation in nanocrystalline form as long acting injection. Mittapelly N; Rachumallu R; Pandey G; Sharma S; Arya A; Bhatta RS; Mishra PR Eur J Pharm Biopharm; 2016 Apr; 101():62-71. PubMed ID: 26850817 [TBL] [Abstract][Full Text] [Related]
12. Coamorphization combined with complexation enhances dissolution of lurasidone hydrochloride and puerarin with synchronized release. Wang S; Heng W; Wang X; He X; Zhang Z; Wei Y; Zhang J; Gao Y; Qian S Int J Pharm; 2020 Oct; 588():119793. PubMed ID: 32827676 [TBL] [Abstract][Full Text] [Related]
13. Elucidating the particle size effect of andrographolide suspensions on their IVIVC performance in oral absorption. Yao S; Chen N; Li M; Wang Q; Sun X; Feng X; Chen Y Eur J Pharm Biopharm; 2022 Oct; 179():65-73. PubMed ID: 36058447 [TBL] [Abstract][Full Text] [Related]
14. Solid dispersion adsorbate technique for improved dissolution and flow properties of lurasidone hydrochloride: characterization using 3 Mahajan A; Surti N; Koladiya P Drug Dev Ind Pharm; 2018 Mar; 44(3):463-471. PubMed ID: 29098883 [TBL] [Abstract][Full Text] [Related]
15. Effects of Temperature and Ionic Strength of Dissolution Medium on the Gelation of Amorphous Lurasidone Hydrochloride. Heng W; Wei Y; Zhou S; Ma D; Gao Y; Zhang J; Qian S Pharm Res; 2019 Mar; 36(5):72. PubMed ID: 30915636 [TBL] [Abstract][Full Text] [Related]
16. Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study. Mittapelly N; Thalla M; Pandey G; Banala VT; Sharma S; Arya A; Mishra S; Mitra K; Shukla S; Mishra PR Pharm Res; 2017 Nov; 34(11):2322-2335. PubMed ID: 28808833 [TBL] [Abstract][Full Text] [Related]
17. Model for Long Acting Injectables (Depot Formulation) Based on Pharmacokinetics and Physical Chemical Properties. Shah JC; Hong J AAPS J; 2022 Mar; 24(3):44. PubMed ID: 35298711 [TBL] [Abstract][Full Text] [Related]
18. Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size. Leng D; Chen H; Li G; Guo M; Zhu Z; Xu L; Wang Y Int J Pharm; 2014 Sep; 472(1-2):380-5. PubMed ID: 24882037 [TBL] [Abstract][Full Text] [Related]
19. Self microemulsifying drug delivery system of lurasidone hydrochloride for enhanced oral bioavailability by lymphatic targeting: In vitro, Caco-2 cell line and in vivo evaluation. Patel MH; Sawant KK Eur J Pharm Sci; 2019 Oct; 138():105027. PubMed ID: 31377133 [TBL] [Abstract][Full Text] [Related]
20. Cryo-TEM and AFM Observation of the Time-Dependent Evolution of Amorphous Probucol Nanoparticles Formed by the Aqueous Dispersion of Ternary Solid Dispersions. Zhao Z; Katai H; Higashi K; Ueda K; Kawakami K; Moribe K Mol Pharm; 2019 May; 16(5):2184-2198. PubMed ID: 30925218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]